Ratings by BTIG (Jeet Mukherjee)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/18/2026 | Nurix | NRIX | Maintain | Buy (N/A) |
|
Details | ||
| 5/15/2026 | Aardvark Therapeutics Inc | AARD | Downgrade | Neutral (Buy) |
6.73 (4.08) |
-39.38% | Details | |
| 5/13/2026 | Arvinas Inc. | ARVN | Maintain | Buy (N/A) |
|
Details | ||
| 5/8/2026 | Verastem | VSTM | Maintain | Buy (N/A) |
|
Details | ||
| 5/1/2026 | Arvinas Inc. | ARVN | Maintain | Buy (Buy) |
|
Details | ||
| 4/20/2026 | Monopar Therapeutics | MNPR | Maintain | Buy (N/A) |
|
Details | ||
| 4/13/2026 | Ascentage Pharma Group | AAPG | Maintain | Buy (Buy) |
|
Details | ||
| 4/10/2026 | Verastem | VSTM | Maintain | Buy (N/A) |
|
Details | ||
| 4/9/2026 | Nurix | NRIX | Maintain | Buy (N/A) |
|
Details | ||
| 3/30/2026 | Monopar Therapeutics | MNPR | Maintain | Buy (N/A) |
|
Details | ||
| 3/24/2026 | Immunitybio Inc | IBRX | Maintain | Buy (N/A) |
|
Details | ||
| 3/18/2026 | Arvinas Inc. | ARVN | Maintain | Buy (N/A) |
|
Details | ||
| 3/17/2026 | Perspective Therapeutics Inc | CATX | Maintain | Buy (Buy) |
|
Details | ||
| 3/11/2026 | Innate Pharma S.A. | ipha | New Coverage | Buy (N/A) |
1.64 (1.81) |
10.37% | Details | |
| 3/11/2026 | Ascentage Pharma Group | AAPG | New Coverage | Buy (N/A) |
24.49 (17.13) |
-30.05% | Details | |
| 3/11/2026 | Verastem | VSTM | New Coverage | Buy (N/A) |
6.39 (4.25) |
-33.49% | Details | |
| 3/11/2026 | Immunitybio Inc | IBRX | New Coverage | Buy (N/A) |
8.01 (7.22) |
-9.86% | Details | |
| 3/11/2026 | ArriVent BioPharma | AVBP | New Coverage | Buy (N/A) |
25.33 (32.70) |
29.1% | Details | |
| 3/2/2026 | Aardvark Therapeutics Inc | AARD | Maintain | Buy (N/A) |
|
Details | ||
| 1/15/2026 | Bicara Therapeutics Inc | BCAX | Maintain | Buy (Buy) |
|
Details | ||
| 1/14/2026 | Nurix | NRIX | Maintain | Buy (Buy) |
|
Details | ||
| 1/14/2026 | Monopar Therapeutics | MNPR | Maintain | Buy (N/A) |
|
Details | ||
| 1/13/2026 | Foghorn Therapeutics | FHTX | Maintain | Buy (Buy) |
|
Details | ||
| 1/8/2026 | Bicara Therapeutics Inc | BCAX | New Coverage | Buy (N/A) |
17.17 (24.55) |
42.98% | Details | |
| 12/18/2025 | Foghorn Therapeutics | FHTX | New Coverage | Buy (N/A) |
4.64 (4.18) |
-9.91% | Details | |
| 12/11/2025 | Aardvark Therapeutics Inc | AARD | Maintain | Buy (N/A) |
|
Details | ||
| 12/9/2025 | Nurix | NRIX | Maintain | Buy (N/A) |
|
Details | ||
| 12/8/2025 | Kymera Therapeutics | KYMR | Maintain | Buy (N/A) |
|
Details | ||
| 11/7/2025 | Aardvark Therapeutics Inc | AARD | New Coverage | Buy (N/A) |
9.87 (6.73) |
-31.81% | Details | |
| 10/30/2025 | Arvinas Inc. | ARVN | Maintain | Buy (N/A) |
|
Details | ||
| 10/10/2025 | Perspective Therapeutics Inc | CATX | New Coverage | Buy (N/A) |
3.86 (3.05) |
-20.98% | Details | |
| 9/24/2025 | Monopar Therapeutics | MNPR | Maintain | Buy (N/A) |
|
Details | ||
| 9/18/2025 | Arvinas Inc. | ARVN | Maintain | Buy (N/A) |
|
Details | ||
| 9/9/2025 | Monopar Therapeutics | MNPR | New Coverage | Buy (N/A) |
41.48 (68.66) |
65.53% | Details | |
| 5/12/2025 | Kymera Therapeutics | KYMR | Maintain | Buy (N/A) |
|
Details | ||
| 5/2/2025 | Arvinas Inc. | ARVN | Maintain | Buy (N/A) |
|
Details | ||
| 4/9/2025 | Nurix | NRIX | Maintain | Neutral (N/A) |
|
Details | ||
| 3/12/2025 | Arvinas Inc. | ARVN | Maintain | Buy (N/A) |
|
Details | ||
| 12/10/2024 | Nurix | NRIX | New Coverage | Buy (N/A) |
20.66 (18.65) |
-9.73% | Details | |
| 12/10/2024 | Arvinas Inc. | ARVN | New Coverage | Buy (N/A) |
25.08 (7.74) |
-69.14% | Details | |
| 12/10/2024 | Kymera Therapeutics | KYMR | New Coverage | Buy (N/A) |
43.65 (99.45) |
127.84% | Details |
